ECSP982684A - Medicamentos - Google Patents

Medicamentos

Info

Publication number
ECSP982684A
ECSP982684A ECSP982684A ECSP982684A EC SP982684 A ECSP982684 A EC SP982684A EC SP982684 A ECSP982684 A EC SP982684A EC SP982684 A ECSP982684 A EC SP982684A
Authority
EC
Ecuador
Prior art keywords
medicines
unconstipated
ibs
treatment
relates
Prior art date
Application number
Other languages
English (en)
Inventor
Allen Wayne Mangel
Allison Ruth Northcutt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority to ECSP982684 priority Critical patent/ECSP982684A/es
Publication of ECSP982684A publication Critical patent/ECSP982684A/es

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere al uso de un antagonista del receptor de 5-HT3, en el tratamiento de pacientes femeninos con IBS no constipados.
ECSP982684 1998-10-05 1998-10-05 Medicamentos ECSP982684A (es)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ECSP982684 ECSP982684A (es) 1998-10-05 1998-10-05 Medicamentos

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ECSP982684 ECSP982684A (es) 1998-10-05 1998-10-05 Medicamentos

Publications (1)

Publication Number Publication Date
ECSP982684A true ECSP982684A (es) 1999-04-13

Family

ID=42043603

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP982684 ECSP982684A (es) 1998-10-05 1998-10-05 Medicamentos

Country Status (1)

Country Link
EC (1) ECSP982684A (es)

Similar Documents

Publication Publication Date Title
HN1998000155A (es) Medicamentos
PT1326643E (pt) Inibicao do efeito emetico da metformina com antagonistas de receptores 5-ht3
IS6750A (is) Samrunnin heterósýklísk súkkínímíð efnasambönd oghliðstæður þeirra, stillar fyrir starfsemi kjarnahormónaviðtaka
TR200200951T2 (tr) Farmasötik kompozisyonlar
ECSP034540A (es) Monohidrato cristalino, procedimiento para su preparacion y su utilizacion para la preparacion de un medicamento
FI960727A0 (fi) Neurokiniiniantagonisteina käyttökelpoiset heterosyklit
AR037109A1 (es) Uso de flibanserina
BR0308429A (pt) Aroilpiridinonas monocìclicas como agentes antiinflamatórios
MA29369B1 (fr) Dosage fixe d'anticorps anti-her
EA200101046A1 (ru) Производные индигоидных бис-индолов
BR9911621A (pt) Bifenil sulfonamidas como antagonista duplos de receptor de angiotensina endotelina
AU5984801A (en) Local anesthetic methods and kits
WO2001066534A3 (en) Cyclic and bicyclic diamino histamine-3 receptor antagonists
BRPI0311189B8 (pt) composições farmacêuticas contendo polimorfo a de flibanserin, bem como seu uso
HUP9800938A2 (hu) NK-1 receptor antagonisták alkalmazása irritációs bélszindróma tüneteinek kezelésére
EA200500213A1 (ru) Диспергируемые таблетки для орального назначения
NO983177L (no) Anvendelse av 1-enantiomeren av centkroman til fremstilling av et farmasaytisk preparat for behandling eller profylakse av brystkreft
EE200300129A (et) Distamütsiini alfa-halogenoakrüloüülderivaadi kasutamine
MXPA05008906A (es) Estra-1,3,5-(10)-trien-3-il-sulfamatos 2-sustituidos, con actividad antitumoral.
TW200503783A (en) Oral pharmaceutical preparation for proton pump antagonists
PE20011080A1 (es) Uso de mirtazapina para el tratamiento de trastornos del sueno
TR200302134T4 (tr) 2-metil-tiazolidin-2,4-dikarboksilik asit ve/veya bunun fizyolojik olarak uygun tuzlarının anti-kanser ajanları olarak kullanımı.
ZA200107985B (en) Substituted benzimidazole, the production thereof and the use thereof as means against parasitic protozoa.
UA91988C2 (ru) Фармацевтическая композиция на основе антагонистов nk2 для применения в педиатрии
MXPA01006319A (es) Uso de los antagonistas del receptor para 5ht, para el tratamiento de sindrome de fatiga cronica.